Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2Lymphoid 1

Conditions

Myelodysplastic Syndromes 54Leukemia, Myeloid, Acute 53Leukemia, Myelogenous, Chronic, BCR-ABL Positive 30Myeloproliferative Disorders 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Lymphoma, Non-Hodgkin 19Leukemia, Myelomonocytic, Chronic 16Primary Myelofibrosis 13Leukemia 11Hodgkin Disease 11Sarcoma 9Polycythemia Vera 9Neuroblastoma 9Histiocytosis, Langerhans-Cell 9Glioma 9Wilms Tumor 8Rhabdoid Tumor 8Neuroectodermal Tumors, Primitive, Peripheral 8Medulloblastoma 8Leukemia, Biphenotypic, Acute 8Hepatoblastoma 8Ependymoma 8Anemia, Refractory, with Excess of Blasts 8Thrombocythemia, Essential 7Rhabdomyosarcoma 7Osteosarcoma 7Myelodysplastic-Myeloproliferative Diseases 7Blast Crisis 7Multiple Myeloma 6Blastic Plasmacytoid Dendritic Cell Neoplasm 6

Interventions

nilotinib 2asciminib 2bosutinib 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Philadelphia Chromosome × Myeloid × 30 days × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-05-27

ASC4START

Novartis

Phase 3 Active not recruiting
568 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡